BRD4-TARGETED THERAPY ABBV-744 CLINICAL DATA NO FURTHER A MYSTERY

In Section A, individuals will receive distinctive doses and schedules of oral ABBV-744 pill to determine Secure dosing program. Extra contributors are going to be enrolled for the determined monotherapy dosign regimen. In Section B, participants will get oral ruxolitinib and ABBV-744 are going to be supplied as "incorporate-on" therapy. In Phase C